Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR139 | Q6DWJ6 | 4/20 | 0.56 |
| ▸ | CAPN1 | P07384 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CTSD | P07339 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.45 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23921539 | 1.00 | GPR139 (0.56) | GPR139CAPN1MEN1KMT2ALMNA | |
| SCHEMBL21554794 | 1.00 | GPR139 (0.56) | GPR139CAPN1MEN1KMT2ALMNA | |
| SCHEMBL21526187 | 1.00 | GPR139 (0.56) | GPR139CAPN1MEN1KMT2ALMNA | |
| SCHEMBL21526228 | 0.89 | CAPN1 (0.68) | GPR139CAPN1MEN1KMT2AALDH1A1 | |
| SCHEMBL21526229 | 0.89 | CAPN1 (0.68) | GPR139CAPN1MEN1KMT2AALDH1A1 | |
| SCHEMBL21554807 | 0.89 | CAPN1 (0.68) | GPR139CAPN1MEN1KMT2AALDH1A1 | |
| SCHEMBL21555034 | 0.88 | GPR139 (0.54) | GPR139CAPN1MEN1KMT2ALMNA | |
| SCHEMBL21554817 | 0.87 | GPR139 (0.58) | GPR139CAPN1MEN1KMT2AALDH1A1 | |
| SCHEMBL21526219 | 0.87 | GPR139 (0.58) | GPR139CAPN1MEN1KMT2AALDH1A1 | |
| SCHEMBL21555104 | 0.87 | GPR139 (0.58) | GPR139CAPN1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3788031-B1 | DIPEPTIDYL KETOAMIDE META-METHOXYPHENYL DERIVATIVES AND USES THEREOF | LANDSTEINER GENMED S L (ES) | 2023-09-27 | — | — | EP | disclosed |
| EP-3788031-B1 | DIPEPTIDYL KETOAMIDE META-METHOXYPHENYL DERIVATIVES AND USES THEREOF | LANDSTEINER GENMED S L (ES) | 2023-09-27 | — | — | EP | disclosed |
| US-11242312-B2 | Dipeptidyl ketoamide meta-methoxyphenyl derivatives and uses thereof | LANDSTEINER GENMED, S.L. (ES) | 2022-02-08 | — | — | US | disclosed |
| US-11242312-B2 | Dipeptidyl ketoamide meta-methoxyphenyl derivatives and uses thereof | LANDSTEINER GENMED, S.L. (ES) | 2022-02-08 | — | — | US | disclosed |
| US-20210317075-A1 | DIPEPTIDYL KETOAMIDE META-METHOXYPHENYL DERIVATIVES AND USES THEREOF | LANDSTEINER GENMED, S.L. (ES) | 2021-10-14 | — | — | US | disclosed |
| US-20210317075-A1 | DIPEPTIDYL KETOAMIDE META-METHOXYPHENYL DERIVATIVES AND USES THEREOF | LANDSTEINER GENMED, S.L. (ES) | 2021-10-14 | — | — | US | disclosed |
| EP-3564211-A1 | DIPEPTIDYL KETOAMIDE META-METHOXYPHENYL DERIVATIVES AND USES THEREOF | LANDSTEINER GENMED, S.L. (ES) | 2019-11-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11242312-B2 | Dipeptidyl ketoamide meta-methoxyphenyl derivatives and uses thereof | DPP4, DPP7, DPP3 | GPR139 3690/4885CAPN1 25/4885MEN1 4709/4885 |
| US-20210317075-A1 | DIPEPTIDYL KETOAMIDE META-METHOXYPHENYL DERIVATIVES AND USES THEREOF | DPP4, DPP7, DPP3 | GPR139 3690/4885CAPN1 25/4885MEN1 4709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.